Chinese Consensus on the Diagnosis and Treatment of Gastric Cancer with Liver Metastases

Overview

Journal Ther Adv Med Oncol

Specialty Oncology

Date 2020 Mar 5

PMID 32127925

Citations 15

Authors

Kecheng Zhang

Lin Chen

Affiliations

Soon will be listed here.

Abstract

Background: The incidence of gastric cancer with liver metastases (GCLM) is 9.9-18.7%, with a median survival time of 11 months and a 5-year survival rate <20%. Multidisciplinary treatment (MDT) is gradually gaining recognition as the most important method. However, specific treatment plans remain unclear. The aim of study was to provide a consensus to improve the diagnosis and treatment of GCLM.

Methods: We brought together experts from relevant medical fields across China, including the Chinese Research Hospital Association Digestive Tumor Committee, Chinese Association of Upper Gastrointestinal Surgeons, Chinese Gastric Cancer Association, and the Gastrointestinal Surgical Group of Chinese Surgical Society Affiliated to Chinese Medical Association, to discuss and formulate this consensus.

Results: A consensus was reached on the diagnosis and treatment of GCLM. Moreover, we have developed a new clinical classification system, the Chinese Type for Gastric Cancer Liver Metastases, based on the likelihood of a surgical treatment being successful.

Conclusions: The MDT mode should be implemented throughout all treatment of GCLM.A Chinese version of this expert consensus has been published in the (Volume 39, Issue 10, p. 405-411). Written permission was obtained from the to disseminate the expert consensus in English.

Citing Articles

Gastric cancer liver metastases in China: a real-world, multicentre, prospective, observational cohort study protocol.

Lu T, Gao Y, Zhang G, Zhang H, Chen Z, Liu Y BMJ Open. 2025; 15(1):e086276.

PMID: 39779263 PMC: 11749313. DOI: 10.1136/bmjopen-2024-086276.

[High expression of CRTAC1 promotes proliferation, migration and immune cell infiltration of gastric cancer by regulating the PI3K/AKT signaling pathway].

Zhang F, Liu G, Dong R, Gao L, Lu W, Gao L Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(12):2421-2433.

PMID: 39725632 PMC: 11683341. DOI: 10.12122/j.issn.1673-4254.2024.12.19.

[High expression of ATP5A1 in gastric carcinoma is correlated with a poor prognosis and enhanced glucose metabolism in tumor cells].

Yang J, Yin L, Duan T, Niu M, He Z, Chen X Nan Fang Yi Ke Da Xue Xue Bao. 2024; 44(5):974-980.

PMID: 38862456 PMC: 11166711. DOI: 10.12122/j.issn.1673-4254.2024.05.20.

Establishment and evaluation of a prognostic model for patients with unresectable gastric cancer liver metastases.

Chang Z, Gao W, Zhang Y, Zhao W, Wu D, Chen L World J Clin Cases. 2024; 12(13):2182-2193.

PMID: 38808342 PMC: 11129128. DOI: 10.12998/wjcc.v12.i13.2182.

TCHH as a Novel Prognostic Biomarker for Patients with Gastric Cancer by Bioinformatics Analysis.

Yu F, Zhao L, Chu S Clin Exp Gastroenterol. 2024; 17:61-74.

PMID: 38434179 PMC: 10906726. DOI: 10.2147/CEG.S451676.

References

Bang Y, Van Cutsem E, Feyereislova A, Chung H, Shen L, Sawaki A . Trastuzumab in combination with chemotherapy versus chemotherapy alone for treatment of HER2-positive advanced gastric or gastro-oesophageal junction cancer (ToGA): a phase 3, open-label, randomised controlled trial. Lancet. 2010; 376(9742):687-97. DOI: 10.1016/S0140-6736(10)61121-X. View

Tiberio G, Ministrini S, Gardini A, Marrelli D, Marchet A, Cipollari C . Factors influencing survival after hepatectomy for metastases from gastric cancer. Eur J Surg Oncol. 2016; 42(8):1229-35. DOI: 10.1016/j.ejso.2016.03.030. View

Xiao Y, Zhang B, Wu Y . Prognostic analysis and liver metastases relevant factors after gastric and hepatic surgical treatment in gastric cancer patients with metachronous liver metastases: a population-based study. Ir J Med Sci. 2018; 188(2):415-424. DOI: 10.1007/s11845-018-1864-4. View

Montagnani F, Crivelli F, Aprile G, Vivaldi C, Pecora I, De Vivo R . Long-term survival after liver metastasectomy in gastric cancer: Systematic review and meta-analysis of prognostic factors. Cancer Treat Rev. 2018; 69:11-20. DOI: 10.1016/j.ctrv.2018.05.010. View

Yoshikawa T, Sasako M, Yamamoto S, Sano T, Imamura H, Fujitani K . Phase II study of neoadjuvant chemotherapy and extended surgery for locally advanced gastric cancer. Br J Surg. 2009; 96(9):1015-22. DOI: 10.1002/bjs.6665. View

Saito T, Nakanishi H, Mochizuki Y, Ito S, Ito Y, Misawa K . Preferential HER2 expression in liver metastases and EGFR expression in peritoneal metastases in patients with advanced gastric cancer. Gastric Cancer. 2014; 18(4):711-9. DOI: 10.1007/s10120-014-0417-4. View

Wang Y, Shen K, Ling J, Gao X, Hou Y, Wang X . Prognostic analysis of combined curative resection of the stomach and liver lesions in 30 gastric cancer patients with synchronous liver metastases. BMC Surg. 2012; 12:20. PMC: 3607939. DOI: 10.1186/1471-2482-12-20. View

Ceniceros L, Chopitea A, Pardo F, Rotellar F, Arbea L, Sola J . Intensified neoadjuvant multimodal approach in synchronous liver metastases from gastric cancer: a single institutional experience. Clin Transl Oncol. 2017; 20(5):658-665. DOI: 10.1007/s12094-017-1767-2. View

Markar S, Mackenzie H, Mikhail S, Mughal M, Preston S, Maynard N . Surgical resection of hepatic metastases from gastric cancer: outcomes from national series in England. Gastric Cancer. 2016; 20(2):379-386. DOI: 10.1007/s10120-016-0604-6. View

10.

Wang W, Liang H, Zhang H, Wang X, Xue Q, Zhang R . Prognostic significance of radical surgical treatment for gastric cancer patients with synchronous liver metastases. Med Oncol. 2014; 31(11):258. DOI: 10.1007/s12032-014-0258-3. View

11.

Jhaveri K, Cleary S, Audet P, Balaa F, Bhayana D, Burak K . Consensus statements from a multidisciplinary expert panel on the utilization and application of a liver-specific MRI contrast agent (gadoxetic acid). AJR Am J Roentgenol. 2015; 204(3):498-509. DOI: 10.2214/AJR.13.12399. View

12.

Guner A, Son T, Cho I, Kwon I, An J, Kim H . Liver-directed treatments for liver metastasis from gastric adenocarcinoma: comparison between liver resection and radiofrequency ablation. Gastric Cancer. 2015; 19(3):951-60. DOI: 10.1007/s10120-015-0522-z. View

13.

Song A, Zhang X, Yu F, Li D, Shao W, Zhou Y . Surgical resection for hepatic metastasis from gastric cancer: a multi- institution study. Oncotarget. 2017; 8(41):71147-71153. PMC: 5642625. DOI: 10.18632/oncotarget.16705. View

14.

Lin J, Lin J, Cao L, Zheng C, Li P, Xie J . Preoperative lymphocyte-to-monocyte ratio as a strong predictor of survival and recurrence for gastric cancer after radical-intent surgery. Oncotarget. 2017; 8(45):79234-79247. PMC: 5668035. DOI: 10.18632/oncotarget.17058. View

15.

Smyth E, Verheij M, Allum W, Cunningham D, Cervantes A, Arnold D . Gastric cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. Ann Oncol. 2016; 27(suppl 5):v38-v49. DOI: 10.1093/annonc/mdw350. View

16.

Liu J, Li J, Zhai R, Wei B, Shao M, Chen L . Predictive factors improving survival after gastric and hepatic surgical treatment in gastric cancer patients with synchronous liver metastases. Chin Med J (Engl). 2012; 125(2):165-71. View

17.

Smyth E, Wotherspoon A, Peckitt C, Gonzalez D, Hulkki-Wilson S, Eltahir Z . Mismatch Repair Deficiency, Microsatellite Instability, and Survival: An Exploratory Analysis of the Medical Research Council Adjuvant Gastric Infusional Chemotherapy (MAGIC) Trial. JAMA Oncol. 2017; 3(9):1197-1203. PMC: 5824280. DOI: 10.1001/jamaoncol.2016.6762. View

18.

Hwang J, Kim S, Jin J, Hong J, Kim M, Jung S . Combination of percutaneous radiofrequency ablation and systemic chemotherapy are effective treatment modalities for metachronous liver metastases from gastric cancer. Clin Exp Metastasis. 2013; 31(1):25-32. PMC: 3892106. DOI: 10.1007/s10585-013-9606-5. View

19.

Arita J, Ono Y, Takahashi M, Inoue Y, Takahashi Y, Matsueda K . Routine Preoperative Liver-specific Magnetic Resonance Imaging Does Not Exclude the Necessity of Contrast-enhanced Intraoperative Ultrasound in Hepatic Resection for Colorectal Liver Metastasis. Ann Surg. 2015; 262(6):1086-91. DOI: 10.1097/SLA.0000000000001085. View

20.

Vogl T, Gruber-Rouh T, Eichler K, Nour-Eldin N, Trojan J, Zangos S . Repetitive transarterial chemoembolization (TACE) of liver metastases from gastric cancer: local control and survival results. Eur J Radiol. 2012; 82(2):258-63. DOI: 10.1016/j.ejrad.2012.10.006. View